Alpha Tau Medical (NASDAQ:DRTS) Shares Gap Up to $8.63

Alpha Tau Medical Ltd. (NASDAQ:DRTSGet Rating) gapped up before the market opened on Tuesday . The stock had previously closed at $8.63, but opened at $10.21. Alpha Tau Medical shares last traded at $11.03, with a volume of 190 shares traded.

A number of equities research analysts recently commented on the company. Piper Sandler assumed coverage on Alpha Tau Medical in a research report on Friday, April 8th. They set an “overweight” rating and a $19.00 price target on the stock. Cantor Fitzgerald assumed coverage on Alpha Tau Medical in a research report on Thursday, April 14th. They set an “overweight” rating and a $20.00 price target on the stock. Finally, Citigroup assumed coverage on Alpha Tau Medical in a report on Monday, April 4th. They set a “buy” rating and a $21.00 price objective on the stock.

The company’s 50 day simple moving average is $8.38.

Alpha Tau Medical (NASDAQ:DRTSGet Rating) last released its quarterly earnings data on Thursday, May 26th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.47). On average, equities research analysts forecast that Alpha Tau Medical Ltd. will post -0.76 EPS for the current year.

A number of hedge funds have recently modified their holdings of DRTS. Clear Street LLC acquired a new stake in Alpha Tau Medical during the first quarter worth approximately $30,000. Ergoteles LLC acquired a new stake in Alpha Tau Medical during the first quarter worth approximately $146,000. Finally, Penserra Capital Management LLC acquired a new stake in Alpha Tau Medical during the first quarter worth approximately $40,000. Hedge funds and other institutional investors own 81.91% of the company’s stock.

About Alpha Tau Medical (NASDAQ:DRTS)

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.

Featured Stories

Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.